Cargando…
Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs
Objective: To determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties. Material and methods: A review of the published me...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920216/ https://www.ncbi.nlm.nih.gov/pubmed/27408684 http://dx.doi.org/10.12688/f1000research.6789.1 |
_version_ | 1782439366895861760 |
---|---|
author | Koltai, Tomas |
author_facet | Koltai, Tomas |
author_sort | Koltai, Tomas |
collection | PubMed |
description | Objective: To determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties. Material and methods: A review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it was tested with this purpose in the experimental and clinical settings. Results: The following pharmaceuticals that fulfill the above mentioned effects, were found: phenytoin, carbamazepine, valproate, lamotrigine, ranolazine, resveratrol, ropivacaine, lidocaine, mexiletine, flunarizine, and riluzole. Each of them are independently described and analyzed. Conclusions: The above mentioned pharmaceuticals have shown anti-metastatic and anti-invasion activity and many of them deserve to be tested in well-planned clinical trials as adjunct therapies for solid tumors and as anti-metastatic agents. Antiepileptic drugs like phenytoin, carbamazepine and valproate and the vasodilator flunarizine emerged as particularly useful for anti-metastatic purposes. |
format | Online Article Text |
id | pubmed-4920216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-49202162016-07-11 Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs Koltai, Tomas F1000Res Review Objective: To determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties. Material and methods: A review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it was tested with this purpose in the experimental and clinical settings. Results: The following pharmaceuticals that fulfill the above mentioned effects, were found: phenytoin, carbamazepine, valproate, lamotrigine, ranolazine, resveratrol, ropivacaine, lidocaine, mexiletine, flunarizine, and riluzole. Each of them are independently described and analyzed. Conclusions: The above mentioned pharmaceuticals have shown anti-metastatic and anti-invasion activity and many of them deserve to be tested in well-planned clinical trials as adjunct therapies for solid tumors and as anti-metastatic agents. Antiepileptic drugs like phenytoin, carbamazepine and valproate and the vasodilator flunarizine emerged as particularly useful for anti-metastatic purposes. F1000Research 2015-07-22 /pmc/articles/PMC4920216/ /pubmed/27408684 http://dx.doi.org/10.12688/f1000research.6789.1 Text en Copyright: © 2015 Koltai T http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Koltai, Tomas Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title | Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title_full | Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title_fullStr | Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title_full_unstemmed | Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title_short | Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
title_sort | voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920216/ https://www.ncbi.nlm.nih.gov/pubmed/27408684 http://dx.doi.org/10.12688/f1000research.6789.1 |
work_keys_str_mv | AT koltaitomas voltagegatedsodiumchannelasatargetformetastaticriskreductionwithrepurposeddrugs |